Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Incidence of Primary central nervous system lymphoma
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Primary central nervous system lymphoma

1 evidence topic · 1 source

United States epidemiology

“Incidence rate increased from 0.1/100,000 to 0.5/100,000 with an AAPC of 5.3% from 1975 to 2017.” (opens the source at this quote in a new tab)